Pharmaceutical - Inflammatory diseases, Oncology


Popular Filters

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site


Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca


Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development


At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet


Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

Immune Pharmaceuticals to acquire EpiCept under stock merger accord


Privately-held Israeli company Immune Pharmaceuticals and US drug developer EpiCept Corp (Nasdaq: EPCT)…

EpiCeptImmune PharmaceuticalsInflammatory diseasesMergers & AcquisitionsOncologyPharmaceutical

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S


Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb


USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

MannKind licenses novel BTK inhibitors to Tolero Pharma


USA-based MannKind Corp (Nasdaq: MNKD) has granted an exclusive worldwide license to privately-held Tolero…

Inflammatory diseasesLicensingMannKindOncologyPharmaceuticalTolero Pharmaceuticals

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen


California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

BioLineRx inks deal with Compugen


Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor


Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

Back to top